Dechra Pharmaceuticals
 | |
| Public (LSE: DPH) | |
| Industry | Pharmaceuticals |
| Founded | 1997 |
| Headquarters | Northwich, United Kingdom |
Key people |
Michael Redmond, (Chairman) Ian Page, (CEO) |
| Revenue | £247.6 million (2016)[1] |
| £52.9 million (2016)[1] | |
| £12.5 million (2016)[1] | |
| Website | www.dechra.com |
Dechra Pharmaceuticals PLC is an English-based manufacturer of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
History
The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.[2] It was first listed on the London Stock Exchange in 2000.[2] In 2007 it bought VetXX, a Danish veterinary products business, for £62m.[3] It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.[4]
Operations
The Company sells pharmaceuticals - mainly for dogs, cats, equine and food producing animals; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. It is organised into two divisions: European Pharmaceuticals and US Pharmaceuticals.[5]
See also
References
- 1 2 3 "Annual Report 2016" (PDF). Retrieved 17 April 2017.
- 1 2 Montague Private Equity announces sale of VetXX
- ↑ "Dechra Pharma to buy VetXX for 61.7 mln stg". Reuters. Retrieved 28 March 2015.
- ↑ "Dechra sells up". Investors Chronicle. 11 July 2013. Retrieved 16 March 2014.
- ↑ "Dechra Pharmaceuticals PLC". dechraplc.com. Retrieved 28 March 2015.
|
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.